McCullough Peter A
Department of Medicine, Divisions of Cardiology, Nutrition and Preventive Medicine, William Beaumont Hospital, Royal Oak, Michigan 48073, USA.
Drugs Today (Barc). 2006 Mar;42(3):177-83. doi: 10.1358/dot.2006.42.3.953590.
Chronic stable angina is common and is a difficult-to-manage problem when patients begin to fail conventional therapy especially when maximal revascularization has been provided. The most promising agent in development is ranolazine, a late sodium channel inhibitor and partial fatty oxidation inhibitor which has unique and desirable anti-ischemic and electrophysiologic properties. This agent is likely to become standard therapy for chronic stable angina and may play a future role in the management of acute coronary syndromes.
